(267 days)
The Cellvizio 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic probes that is intended to allow imaging of the internal microstructure of tissues in anatomical tracts, i.e., gastrointestinal or respiratory, accessed by an endoscope or endloscopic accessories.
The GastroFlex M series of Confocal Miniprobes are intended to allow imaging of the internal microstructure of tissues in the upper gastrointestinal tract including biliary and pancreatic ducts, accessed by an endoscope or endloscopic accessories.
The Cellvizio 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic probes that is intended to allow imaging of the internal microstructure of tissues in anatomical tracts, i.e., gastrointestinal.
The AQ-Flex 19 member of the GastroFlex M series of Confocal Miniprobes can be used within anatomical tracts, i.e., gastrointestinal, accessed by an endoscope or endoscopic accessories, including through EUS-FNA needles.
The Cellvizio® 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic probes that are intended to allow imaging of the internal microstructure of tissues.
The Uroflex™B and CystoFlex™F Confocal Miniprobes can be used within anatomical tracts, i.e. Urinary, including, but not limited to, urethra, bladder, and ureter, accessed through an endoscopic accessories.
The Cellvizio® 100 Series System with Confocal Miniprobes™ is a confocal laser system with fiber optic probes that are intended to allow imaging of the internal microstructure of tissues.
The CystoFlex UHD R Confocal Miniprobe can be used within anatomical tracts, i.e., urinary, including, but not limited to urethra, bladder, and ureter, accessed through an endoscope or endoscopic accessories.
AlveoFlex™. ColoFlex™ UHD, GastroFlex™ UHD, CholangioFlex™, AQ-Flex™. UroFlex™ B and CystoFlex™ UHD R are Confocal Miniprobes which are compatible with specific high level disinfection and low temperature sterilization methods as described in the reprocessing instructions.
Materials, design and intended use of the aforementioned Confocal Miniprobes remain exactly the same as what were previously cleared in K111047. K122042. K123676. K132389 and K141358 respectively.
Low temperature sterilization methods will be added to the reprocessing instructions. Compatibility and efficacy of these methods with Confocal Miniprobes have been validated. The extent of validation testing relevant to this submission is provided below
Verification and validation testing confirm that GastroFlex™ UHD, ColoFlex™ UHD, AlveoFlex™ and CholangioFlex™ Confocal Miniprobes™ can be reprocessed safely using STERRAD® sterilization systems 100S and 100NX (EXPRESS) according to reprocessing instructions.
The provided text describes a 510(k) premarket notification for a medical device family (Cellvizio 100 Series System with Confocal Miniprobes), specifically focusing on the addition of low-temperature sterilization methods to their reprocessing instructions. The primary study presented is a performance evaluation to confirm the compatibility and efficacy of these sterilization methods.
Here's the breakdown of the acceptance criteria and the study that proves the device meets them, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
Device Family: Cellvizio 100 Series System with Confocal Miniprobes
(Including AQ-Flex™, UroFlex™ B, CystoFlex™ UHD R, ColoFlex™ UHD, GastroFlex™ UHD, CholangioFlex™, and AlveoFlex™)
| Acceptance Criteria Category | Specific Criteria | Reported Device Performance |
|---|---|---|
| Sterilization Efficacy | Achieve a Sterility Assurance Level (SAL) of $10^{-6}$ | Confirmed: "Sterilization validation was performed on the products to confirm sterility assurance levels (SAL) of $10^{-6}$." |
| Material Compatibility | Components remain visually intact & functional | Confirmed: "Functional testing post sterilization validation included visual assessment of component condition, insertion and removal tests, tensile strength and optical performance assessment. These tests also confirmed material compatibility." Specific Device Performance: - AQ-Flex™ 19, UroFlex™ B, and CystoFlex™ UHD R: "can safely and efficiently be reprocessed using STERRAD® 50, 200, 100S, 100NX EXPRESS and 100NX Duo cycles according to reprocessing instructions. Chemical resistance [material compatibility implied] as well as a sterility assurance level (SAL) of 10-$^6$ has been demonstrated." - GastroFlex™ UHD, ColoFlex™ UHD, AlveoFlex™ and CholangioFlex™: "Can be reprocessed using STERRAD® sterilization systems 100S, 100NX EXPRESS according to reprocessing instructions... The compatibility with these sterilization methods has been demonstrated." |
| Functional Performance | Maintain mechanical (insertion/removal/tensile) & optical performance after reprocessing | Confirmed: "Functional testing post sterilization validation included visual assessment of component condition, insertion and removal tests, tensile strength and optical performance assessment." |
| Biocompatibility | No unacceptable biological response after contact with reprocessed device | Confirmed: "Biocompatibility per relevant portions of ISO 10993-1" was tested for Cytotoxicity, Sensitization, and Irritation. The summary implies these tests were met as part of demonstrating safe reprocessing. |
2. Sample size used for the test set and the data provenance
- Sample Size: The document does not explicitly state the numerical sample size for the "test set" (i.e., the number of miniprobes subjected to the full battery of sterilization and functional tests). It refers to "the products" and specific models (AQ-Flex™ 19, UroFlex™ B, CystoFlex™ UHD R, GastroFlex™ UHD, ColoFlex™ UHD, AlveoFlex™, CholangioFlex™). Typically, for sterilization validation, multiple units of each device type and/or material are tested.
- Data Provenance: The data is likely prospective as it involves specific validation testing for the new sterilization methods. There's no information about the country of origin of the data beyond the applicant being "Mauna Kea Technologies, F-75010 Paris, France."
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
Not applicable. This study focuses on validating physical and functional properties (sterilization efficacy, material compatibility, functional performance, biocompatibility) rather than a diagnostic performance where expert ground truth would be required. The "ground truth" here is objective measurements against established engineering and biological standards (e.g., SAL of $10^{-6}$, ISO 10993-1).
4. Adjudication method for the test set
Not applicable. Adjudication methods (like 2+1, 3+1) are typically used for clinical studies involving reader interpretations of images or data where a consensus among experts is needed to establish ground truth. This study involves laboratory validation.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is not a study assessing AI performance or human reader performance. It's a technical validation study for reprocessing instructions of an endoscope accessory.
6. If a standalone (i.e. algorithm only, without human-in-the-loop performance) was done
Not applicable. This device is not an AI algorithm. It is a medical device (confocal miniprobe) that requires human operation with an endoscope, and the study focuses on its physical properties after reprocessing.
7. The type of ground truth used
The ground truth used for this study is based on objective engineering and biological standards.
- Sterilization Efficacy: Sterility Assurance Level (SAL) of $10^{-6}$ as per industry standards and regulatory requirements. This is typically verified through biological indicator testing.
- Material Compatibility & Functional Performance: Performance against predefined specifications for visual integrity, mechanical function (e.g., tensile strength, insertion/removal forces), and optical performance after a specified number of reprocessing cycles.
- Biocompatibility: Conformance to relevant portions of ISO 10993-1 (e.g., passing tests for cytotoxicity, sensitization, irritation).
8. The sample size for the training set
Not applicable. This is a validation study for physical device properties, not a machine learning study that would involve training data.
9. How the ground truth for the training set was established
Not applicable. As there is no training set for this type of validation, there is no ground truth established for it.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States of America. The seal features the department's name encircling a stylized representation of a human figure. The figure is composed of three profiles facing right, symbolizing the department's focus on health and well-being. The text is arranged in a circular pattern around the central emblem.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 22, 2015
Mauna Kea Technologies Mr. Michael A. Daniel Daniel & Daniel Consulting 340 Jones Lane Gardneville, Nevada 89460
Re: K150831
Trade/Device Name: AO-Flex™ (K123676); 2) UroFlex™ B (K132389); 3) CystoFlex™ UHD R (K141358); 4) ColoFlex™ UHD (K111047); GastroFlex™ UHD (Cholangioflex™) (K111047); 6) AlveoFlex™ (K111047); and 7) GastroFlex™ (K122042)
Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope and accessories Regulatory Class: Class II Product Code: OWN Dated: November 20, 2015 Received: November 23, 2015
Dear Mr. Daniel:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
{1}------------------------------------------------
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Binita S. Ashar -S
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
6. Indications for Use Statement
| DEPARTMENT OF HEALTH AND HUMAN SERVICESFood and Drug Administration | Form Approved: OMB No. 0910-0120 |
|---|---|
| Indications for Use | Expiration Date: January 31, 2017See PRA Statement below. |
| 510(k) Number (if known) | K150831 |
|---|---|
| Device Name | 1) AQ-Flex™ (K123676); 2) UroFlex™ B (K132389); 3) CystoFlex™ UHD R (K141358); 4) ColoFlex™ UHD (K111047);5) GastroFlex™ UHD (Cholangioflex™) (K111047); 6) AlveoFlex™ (K111047); and 7) GastroFlex™ M (K122042) |
| Indications for Use (Describe) | |
| ColoFlex™ UHD (K111047); GastroFlex™ UHD (Cholangioflex™) (K111047); AlveoFlex™ (K111047): |
The Cellvizio 100 Series System with Confocal Miniprobes is a confocal laser system with
fiber optic probes that is intended to allow imaging of the internal microstructure of tissues in
anatomical tracts, i.e., gastrointestinal or respiratory, accessed by an endoscope or endloscopic
accessories.
| GastroFlex™ M (K122042): | |
|---|---|
| -------------------------- | -- |
The GastroFlex M series of Confocal Miniprobes are intended to allow imaging of the internal
microstructure of tissues in the upper gastrointestinal tract including biliary and pancreatic ducts,
accessed by an endoscope or endloscopic accessories.
| AQ-Flex™ (K123676): | |
|---|---|
| --------------------- | -- |
The Cellvizio 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic
probes that is intended to allow imaging of the internal microstructure of tissues in anatomical tracts,
i.e., gastrointestinal.
The AQ-Flex 19 member of the GastroFlex M series of Confocal Miniprobes can be used within
anatomical tracts, i.e., gastrointestinal, accessed by an endoscope or endoscopic accessories,
including through EUS-FNA needles.
CONTINUED ON NEXT PAGE
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
FORM FDA 3881 (8/14)
Page 1 of 2
PSC Publishing Services (301) 443-6740 EF
{3}------------------------------------------------
| DEPARTMENT OF HEALTH AND HUMAN SERVICESFood and Drug Administration | Form Approved: OMB No. 0910-0120 |
|---|---|
| Indications for Use | Expiration Date: January 31, 2017See PRA Statement below. |
| 510(k) Number (if known) | K150831 |
| Device Name | 1) AQ-Flex™ (K123676); 2) UroFlex™ B (K132389); 3) CystoFlex™ UHD R (K141358); 4) ColoFlex™ UHD (K111047);5) GastroFlex™ UHD (Cholangioflex™) (K111047); 6) AlveoFlex™ (K111047); and 7) GastroFlex™ M (K122042) |
| Indications for Use (Describe) | |
| CONTINUED FROM PREVIOUS PAGE | |
| UroFlex™ B (K132389): | |
| The Cellvizio® 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic probes that areintended to allow imaging of the internal microstructure of tissues. | |
| The Uroflex™B and CystoFlex™F Confocal Miniprobes can be used within anatomical tracts, i.e. Urinary, including, butnot limited to, urethra, bladder, and ureter, accessed through an endoscopic accessories. | |
| CystoFlex™ UHD R (K141358) | |
| The Cellvizio® 100 Series System with Confocal Miniprobes™ is a confocal laser system with fiber optic probes that areintended to allow imaging of the internal microstructure of tissues. | |
| The CystoFlex UHD R Confocal Miniprobe can be used within anatomical tracts, i.e., urinary, including, but not limitedto, urethra, bladder, and ureter, accessed through an endoscope or endoscopic accessories. | |
| Type of Use (Select one or both, as applicable) | |
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995, | |
| DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.The burden time for this collection of information is estimated to average 79 hours per response, including thetime to review instructions, search existing data sources, gather and maintain the data needed and completeand review the collection of information. Send comments regarding this burden estimate or any other aspectof this information collection, including suggestions for reducing this burden, to: | |
| Department of Health and Human ServicesFood and Drug AdministrationOffice of Chief Information OfficerPaperwork Reduction Act (PRA) Staff |
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
*An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (8/14)
Page 1 of 1
PSC Publishing Services (301) 443-6740 EF
{4}------------------------------------------------
7. Premarket Notification 510(k) Summary
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
| 510(k) Number: | |
|---|---|
| Applicant Information: | |
| Date Prepared: | March 28, 2015 |
| Name: | Mauna Kea Technologies |
| Address: | 9 rue d'Enghien |
| F-75010 Paris, France | |
| Phone: | +33 1 48 24 03 45 |
| Fax: | +33 1 48 24 12 18 |
| Contact Person: | Michael A Daniel, Consultant |
| Phone Number: | (415) 407-0223 |
| Office: | (775) 392-2970 |
| Facsimile Number: | (610) 545-0799 |
| Device Information: | |
| Device Trade Name: | Cellvizio® 100 Series System with Confocal Miniprobes |
| Common Name: | Endoscope and Accessories |
| Classification Name(s): | Confocal Optical Imaging |
| Product Code/ Regulation: | OWN / 21 CFR 876.1500 |
| Classification: | Class II |
Predicate Device:
- The Cellvizio 100 Series System with Confocal Miniprobes (ColoFlexTM UHD, ● GatroFlexTM UHD and AlveoFlexTM) have been cleared in K111047.
- The CholangioFlex™ has been cleared in K122042 ●
- The compatibility with low temperature sterilization systems has been cleared for AQ-Flex™ 19 (K123676), UroFlex™ B (K132389) and CystoFlex™ UHD R (K141358)
{5}------------------------------------------------
Device Description:
AlveoFlex™. ColoFlex™ UHD, GastroFlex™ UHD, CholangioFlex™, AQ-Flex™. UroFlex™ B and CystoFlex™ UHD R are Confocal Miniprobes which are compatible with specific high level disinfection and low temperature sterilization methods as described in the reprocessing instructions.
Materials, design and intended use of the aforementioned Confocal Miniprobes remain exactly the same as what were previously cleared in K111047. K122042. K123676. K132389 and K141358 respectively.
Low temperature sterilization methods will be added to the reprocessing instructions. Compatibility and efficacy of these methods with Confocal Miniprobes have been validated. The extent of validation testing relevant to this submission is provided below
Verification and validation testing confirm that GastroFlex™ UHD, ColoFlex™ UHD, AlveoFlex™ and CholangioFlex™ Confocal Miniprobes™ can be reprocessed safely using STERRAD® sterilization systems 100S and 100NX (EXPRESS) according to reprocessing instructions.
Indications for Use:
ColoFlex™ UHD (K111047); GastroFlex™ UHD (K111047); AlveoFlex™ (K111047):
The Cellvizio 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic probes that is intended to allow imaging of the internal microstructure of tissues in anatomical tracts, i.e., gastrointestinal or respiratory, accessed by an endoscope or endoscopic accessories.
GastroFlex™ M (CholangioFlex™) (K122042):
The GastroFlex M series of Confocal Miniprobes are intended to allow imaging of the internal microstructure of tissues in the upper gastrointestinal tract including biliary and pancreatic ducts, accessed by an endoscope or endoscopic accessories.
AO-Flex™ 19 (K123676):
The Cellvizic 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic probes that is intended to allow imaging of the internal microstructure of tissues in anatomical tracts, i.e., gastrointestinal.
The AQ-Flex 19 member of the GastroFlex M series of Confocal Miniprobes can be used within anatomical tracts, i.e., gastrointestinal, accessed by an endoscope or endoscopic accessories, including through EUS-FNA needles.
UroFlex™ B (K132389):
{6}------------------------------------------------
The Cellvizio® 100 Series System with Confocal Miniprobes is a confocal laser system with fiber optic probes that are intended to allow imaging of the internal microstructure of tissues.
The UroflexTMB and CystoFlex™F Confocal Miniprobes can be used within anatomical tracts, i.e. Urinary, including, but not limited to, urethra, bladder, and ureter, accessed through an endoscope or endoscopic accessories.
CystoFlex™ UHD R (K141358)
The Cellvizio® 100 Series System with Confocal Miniprobes™ is a confocal laser system with fiber optic probes that are intended to allow imaging of the internal microstructure of tissues.
The CystoFlex UHD R Confocal Miniprobe can be used within anatomical tracts, i.e., urinary, including, but not limited to urethra, bladder, and ureter, accessed through an endoscope or endoscopic accessories.
Comparison to Predicate Device:
No change is being made to the predicate devices in term of design, materials nor intended use. Subject devices are identical to previously cleared devices (AlveoFlex™, ColoFlex™ UHD, GastroFlex™ UHD (K111047)), CholangioFlex™ (K122042), UroFlex™ B (K132389), AQ-Flex™ 19 (K123676), CystoFlex™ UHD R (K141358). Further, all Confocal Miniprobes exhibit a similar external geometry. The differences between models are in the internal optical components that allow for different performance characteristics but do not substantially change the outer geometry. Further details regarding probe differences are described in tables 3, 4 and 5 of this submission and in the previously cleared K141358. K132389, K123676, K122042 and K111047 submissions and their corresponding Request for Additional Information submissions.
The only change in this submission is the addition of low temperature sterilization systems to the reprocessing instructions of the previously cleared Confocal Miniprobes (AlveoFlexIM, ColoFlex™ UHD, GastroFlex™ UHD, CholangioFlex™, UroFlex™ B, AQ-Flex™ 19, CystoFlex™ UHD R). This change does not alter the fundamental technology and purpose of the previously cleared Confocal Miniprobes™.
The extension of the previously cleared AQ-Flex™ 19, UroFlex™ B and CystoFlex™ UHD R compatibility with sterilization to CholangioFlex™, ColoFlex™ UHD, GastroFlex™ UHD and AlveoFlex™ is demonstrated based on similarities in terms of design and materials between these products.
Performance Evaluation:
The following performance testing was completed:
- . Functional testing post sterilization validation included visual assessment of component condition, insertion and removal tests, tensile strength and optical performance assessment. These tests also confirmed material compatibility.
- Sterilization validation was performed on the products to confirm sterility assurance ● levels (SAL) of 10-6
{7}------------------------------------------------
- . Biocompatibility per relevant portions of ISO 10993-1
- o Cytotoxicity
- o Sensitization
- o Irritation
Summary:
Based upon the intended use, indications for use, product technical information, performance testing provided in this special 510(k) submission
- AQ-Flex™ 19, UroFlex™ B and CystoFlex™ UHD R can safely and efficiently be ● reprocessed using STERRAD® 50, 200, 100S, 100NX EXPRESS and 100NX Duo cycles according to reprocessing instructions. Chemical resistance as well as a sterility assurance level (SAL) of 10° has been demonstrated.
- GastroFlex™ UHD, ColoFlex™ UHD, AlveoFlex™ and CholangioFlex™ Confocal . Miniprobes can be reprocessed using STERRAD® sterilization systems 100S, 100NX EXPRESS according to reprocessing instructions as an alternative to previously cleared high-level disinfection methods. The compatibility with these sterilization methods has been demonstrated.
§ 876.1500 Endoscope and accessories.
(a)
Identification. An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification —(1)Class II (special controls). The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.